Preclinical studies in murine models have shown that IL-6 promotes atherosclerosis and possibly plaque vulnerability and that injection of IL-6 results in increased CRP, TNF-α, and fibrinogen levels [35,36,37]. The gene discussed is CRP; the disease is atherosclerosis.